Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, Antonietta Falcone, Maria Teresa Petrucci, Laura Cesini, Francesco Di Raimondo, Concetta Conticello, Roberto Ria, Lucio Catalano, Dalila Salvatore, Lucia Mastrullo, Alfredo Gagliardi, Oreste Villani, Giuseppe Pietrantuono, Giovanni D’Arena, Giovanna Mansueto, Sara Bringhen, Mariella Genuardi, Nicola Di RenzoGiovanni Reddiconto, Alberto Fragasso, Tommaso Caravita, Daniele Scapicchio, Gioacchino Marziano, Mario Boccadoro, Silvia Mangiacavalli, Alessandro Corso

Research output: Contribution to journalArticle

Abstract

Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Salvage Therapy
Multiple Myeloma
Therapeutics
Recurrence
Drug Combinations
Disease-Free Survival
Observational Studies
Retrospective Studies
Bortezomib
Transplants
Survival

Keywords

  • Bortezomib
  • First relapse
  • Myeloma
  • Re-treatment
  • Salvage therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). / Musto, Pellegrino; Simeon, Vittorio; Cascavilla, Nicola; Falcone, Antonietta; Petrucci, Maria Teresa; Cesini, Laura; Di Raimondo, Francesco; Conticello, Concetta; Ria, Roberto; Catalano, Lucio; Salvatore, Dalila; Mastrullo, Lucia; Gagliardi, Alfredo; Villani, Oreste; Pietrantuono, Giuseppe; D’Arena, Giovanni; Mansueto, Giovanna; Bringhen, Sara; Genuardi, Mariella; Di Renzo, Nicola; Reddiconto, Giovanni; Fragasso, Alberto; Caravita, Tommaso; Scapicchio, Daniele; Marziano, Gioacchino; Boccadoro, Mario; Mangiacavalli, Silvia; Corso, Alessandro.

In: Annals of Hematology, 01.01.2018.

Research output: Contribution to journalArticle

Musto, P, Simeon, V, Cascavilla, N, Falcone, A, Petrucci, MT, Cesini, L, Di Raimondo, F, Conticello, C, Ria, R, Catalano, L, Salvatore, D, Mastrullo, L, Gagliardi, A, Villani, O, Pietrantuono, G, D’Arena, G, Mansueto, G, Bringhen, S, Genuardi, M, Di Renzo, N, Reddiconto, G, Fragasso, A, Caravita, T, Scapicchio, D, Marziano, G, Boccadoro, M, Mangiacavalli, S & Corso, A 2018, 'Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)', Annals of Hematology. https://doi.org/10.1007/s00277-018-3524-1
Musto, Pellegrino ; Simeon, Vittorio ; Cascavilla, Nicola ; Falcone, Antonietta ; Petrucci, Maria Teresa ; Cesini, Laura ; Di Raimondo, Francesco ; Conticello, Concetta ; Ria, Roberto ; Catalano, Lucio ; Salvatore, Dalila ; Mastrullo, Lucia ; Gagliardi, Alfredo ; Villani, Oreste ; Pietrantuono, Giuseppe ; D’Arena, Giovanni ; Mansueto, Giovanna ; Bringhen, Sara ; Genuardi, Mariella ; Di Renzo, Nicola ; Reddiconto, Giovanni ; Fragasso, Alberto ; Caravita, Tommaso ; Scapicchio, Daniele ; Marziano, Gioacchino ; Boccadoro, Mario ; Mangiacavalli, Silvia ; Corso, Alessandro. / Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). In: Annals of Hematology. 2018.
@article{27063cfedff649f6b984646e9434c14e,
title = "Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)",
abstract = "Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71{\%}, including 40{\%} partial responses, 24{\%} very good partial responses, and 7{\%} complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.",
keywords = "Bortezomib, First relapse, Myeloma, Re-treatment, Salvage therapy",
author = "Pellegrino Musto and Vittorio Simeon and Nicola Cascavilla and Antonietta Falcone and Petrucci, {Maria Teresa} and Laura Cesini and {Di Raimondo}, Francesco and Concetta Conticello and Roberto Ria and Lucio Catalano and Dalila Salvatore and Lucia Mastrullo and Alfredo Gagliardi and Oreste Villani and Giuseppe Pietrantuono and Giovanni D’Arena and Giovanna Mansueto and Sara Bringhen and Mariella Genuardi and {Di Renzo}, Nicola and Giovanni Reddiconto and Alberto Fragasso and Tommaso Caravita and Daniele Scapicchio and Gioacchino Marziano and Mario Boccadoro and Silvia Mangiacavalli and Alessandro Corso",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00277-018-3524-1",
language = "English",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

AU - Musto, Pellegrino

AU - Simeon, Vittorio

AU - Cascavilla, Nicola

AU - Falcone, Antonietta

AU - Petrucci, Maria Teresa

AU - Cesini, Laura

AU - Di Raimondo, Francesco

AU - Conticello, Concetta

AU - Ria, Roberto

AU - Catalano, Lucio

AU - Salvatore, Dalila

AU - Mastrullo, Lucia

AU - Gagliardi, Alfredo

AU - Villani, Oreste

AU - Pietrantuono, Giuseppe

AU - D’Arena, Giovanni

AU - Mansueto, Giovanna

AU - Bringhen, Sara

AU - Genuardi, Mariella

AU - Di Renzo, Nicola

AU - Reddiconto, Giovanni

AU - Fragasso, Alberto

AU - Caravita, Tommaso

AU - Scapicchio, Daniele

AU - Marziano, Gioacchino

AU - Boccadoro, Mario

AU - Mangiacavalli, Silvia

AU - Corso, Alessandro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.

AB - Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.

KW - Bortezomib

KW - First relapse

KW - Myeloma

KW - Re-treatment

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85055693033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055693033&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3524-1

DO - 10.1007/s00277-018-3524-1

M3 - Article

AN - SCOPUS:85055693033

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -